Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion.

Bachireddy P, Hainz U, Rooney M, Pozdnyakova O, Aldridge J, Zhang W, Liao X, Hodi FS, O'Connell K, Haining WN, Goldstein NR, Canning CM, Soiffer RJ, Ritz J, Hacohen N, Alyea EP 3rd, Kim HT, Wu CJ.

Blood. 2014 Feb 27;123(9):1412-21. doi: 10.1182/blood-2013-08-523001. Epub 2013 Dec 19.

2.

Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.

Burkhardt UE, Hainz U, Stevenson K, Goldstein NR, Pasek M, Naito M, Wu D, Ho VT, Alonso A, Hammond NN, Wong J, Sievers QL, Brusic A, McDonough SM, Zeng W, Perrin A, Brown JR, Canning CM, Koreth J, Cutler C, Armand P, Neuberg D, Lee JS, Antin JH, Mulligan RC, Sasada T, Ritz J, Soiffer RJ, Dranoff G, Alyea EP, Wu CJ.

J Clin Invest. 2013 Sep;123(9):3756-65. doi: 10.1172/JCI69098. Epub 2013 Aug 5.

3.

Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients.

Brusic A, Hainz U, Wadleigh M, Neuberg D, Su M, Canning CM, Deangelo DJ, Stone RM, Lee JS, Mulligan RC, Ritz J, Dranoff G, Sasada T, Wu CJ.

Oncoimmunology. 2012 Oct 1;1(7):1095-1103.

4.

Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans.

Lin Y, Zhang L, Cai AX, Lee M, Zhang W, Neuberg D, Canning CM, Soiffer RJ, Alyea EP, Ritz J, Hacohen N, Means TK, Wu CJ.

J Clin Invest. 2011 Apr;121(4):1574-84. doi: 10.1172/JCI44581. Epub 2011 Mar 14.

5.

Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.

Zhang W, Choi J, Zeng W, Rogers SA, Alyea EP, Rheinwald JG, Canning CM, Brusic V, Sasada T, Reinherz EL, Ritz J, Soiffer RJ, Wu CJ.

Clin Cancer Res. 2010 May 15;16(10):2729-39. doi: 10.1158/1078-0432.CCR-10-0415. Epub 2010 May 11.

6.

Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens.

Marina O, Hainz U, Biernacki MA, Zhang W, Cai A, Duke-Cohan JS, Liu F, Brusic V, Neuberg D, Kutok JL, Alyea EP, Canning CM, Soiffer RJ, Ritz J, Wu CJ.

Cancer Res. 2010 Feb 15;70(4):1344-55. doi: 10.1158/0008-5472.CAN-09-3143. Epub 2010 Feb 2.

7.

Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.

Biernacki MA, Marina O, Zhang W, Liu F, Bruns I, Cai A, Neuberg D, Canning CM, Alyea EP, Soiffer RJ, Brusic V, Ritz J, Wu CJ.

Cancer Res. 2010 Feb 1;70(3):906-15. doi: 10.1158/0008-5472.CAN-09-2303. Epub 2010 Jan 26.

8.

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML.

Clin Cancer Res. 1997 Mar;3(3):409-17.

9.

Alterations in Ca2+ signal transduction in critically ill surgical patients.

Burke PA, Canning CM, Chartier S, Lazo S, Daley J, Forse RA, Ritz J.

Surgery. 1994 Aug;116(2):378-86; discussion 386-7.

PMID:
8048003

Supplemental Content

Loading ...
Support Center